Evidence map›Paper›PMID 41287656›Full record

ReviewCureus2025

A Systematic Review of Treatment Approaches for Individuals With Coexisting Diabetes and Substance Use Disorder.

Bilal Husain, Suchismita Ray, Barbara Tafuto

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bilal HusainDepartment of Health Informatics, Rutgers University, Newark, USA.
Suchismita RayDepartment of Health Informatics, Rutgers University, Newark, USA.
Barbara TafutoDepartment of Health Informatics, Rutgers University, Newark, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a chronic metabolic disease that is widespread and has negative consequences for health and well-being. Substance use disorder (SUD) is characterized by the uncontrolled use of substances, including tobacco, alcohol, marijuana, and illicit drugs, leading to impaired mental and physical health. Individuals with coexisting diabetes and SUD experience exacerbated consequences, including increased susceptibility to diabetes-related complications, hospitalizations, and mortality. Additionally, this unique population utilizes significant hospital resources, leading to a burden on the healthcare system. This systematic review is designed to synthesize current literature on individuals with coexisting diabetes and SUD, focusing on current treatments. A systematic search of the PubMed and Embase databases was conducted using Medical Subject Headings and keyword strategies. After removing duplicates, studies were screened based on predefined inclusion and exclusion criteria, including relevance to the topic, publication within the past 10 years, availability of full-text articles, English language, and sufficient scope. From an initial pool of 1,135 articles, 1,126 were excluded for not meeting eligibility, leaving nine retrospective studies for inclusion. Treatment strategies identified for individuals with coexisting diabetes and SUD encompassed pharmacotherapies (semaglutide and buprenorphine-naloxone), diligent adherence to SUD treatment, care management programs targeting individuals with multimorbidity, and reinforcers or rewards to either treatment adherence or drug abstinence. Although these approaches showed improvement in health outcomes, they primarily addressed diabetes and SUD separately. Additionally, few studies incorporated behavioral therapies, such as mindfulness-based interventions, despite their potential relevance to this population. This review highlights the current treatment approaches for individuals with coexisting diabetes and SUD. The findings underscore the need for integrated care models that simultaneously address both conditions. Incorporating behavioral interventions alongside standard care strategies may offer a more comprehensive and effective treatment framework for this underserved population.

Indexed as

buprenorphine-naloxonecare managementcoexisting diseasesdiabetes mellitusglp-1 receptor agonistssemaglutidesubstance use disordersystematic review (syst. rev.)treatment approach

Identifiers

PMID41287656
PMCPMC12640742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.